<?xml version='1.0' encoding='utf-8'?>
<document id="24925712"><sentence text="Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects."><entity charOffset="67-77" id="DDI-PubMed.24925712.s1.e0" text="sofosbuvir" /><entity charOffset="81-91" id="DDI-PubMed.24925712.s1.e1" text="ledipasvir" /><entity charOffset="125-137" id="DDI-PubMed.24925712.s1.e2" text="norgestimate" /><entity charOffset="138-155" id="DDI-PubMed.24925712.s1.e3" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e0" e2="DDI-PubMed.24925712.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e0" e2="DDI-PubMed.24925712.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e0" e2="DDI-PubMed.24925712.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e0" e2="DDI-PubMed.24925712.s1.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e1" e2="DDI-PubMed.24925712.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e1" e2="DDI-PubMed.24925712.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e1" e2="DDI-PubMed.24925712.s1.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e2" e2="DDI-PubMed.24925712.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s1.e2" e2="DDI-PubMed.24925712.s1.e3" /></sentence><sentence text="This study evaluated the potential for a drug-drug interaction between HCV direct-acting antivirals sofosbuvir or ledipasvir and oral hormonal contraceptive (OC) norgestimate/ethinyl estradiol (norgestimate 0"><entity charOffset="100-110" id="DDI-PubMed.24925712.s2.e0" text="sofosbuvir" /><entity charOffset="114-124" id="DDI-PubMed.24925712.s2.e1" text="ledipasvir" /><entity charOffset="162-174" id="DDI-PubMed.24925712.s2.e2" text="norgestimate" /><entity charOffset="175-192" id="DDI-PubMed.24925712.s2.e3" text="ethinyl estradiol" /><entity charOffset="194-206" id="DDI-PubMed.24925712.s2.e4" text="norgestimate" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e0" e2="DDI-PubMed.24925712.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e0" e2="DDI-PubMed.24925712.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e0" e2="DDI-PubMed.24925712.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e0" e2="DDI-PubMed.24925712.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e0" e2="DDI-PubMed.24925712.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e1" e2="DDI-PubMed.24925712.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e1" e2="DDI-PubMed.24925712.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e1" e2="DDI-PubMed.24925712.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e1" e2="DDI-PubMed.24925712.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e2" e2="DDI-PubMed.24925712.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e2" e2="DDI-PubMed.24925712.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e2" e2="DDI-PubMed.24925712.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e3" e2="DDI-PubMed.24925712.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s2.e3" e2="DDI-PubMed.24925712.s2.e4" /></sentence><sentence text="18/0" /><sentence text="215/0" /><sentence text="25 mg with ethinyl estradiol 25 Î¼g)"><entity charOffset="11-28" id="DDI-PubMed.24925712.s5.e0" text="ethinyl estradiol" /></sentence><sentence text=" This was a 112-day, open-label, fixed-sequence pharmacokinetic (PK) study in healthy female subjects that included a lead-in cycle (OC only; N = 21), cycle 1 (OC only; N = 15), cycle 2 (OC + sofosbuvir; N = 15), and cycle 3 (OC + ledipasvir; N = 15)"><entity charOffset="142-143" id="DDI-PubMed.24925712.s6.e0" text="N" /><entity charOffset="169-170" id="DDI-PubMed.24925712.s6.e1" text="N" /><entity charOffset="204-205" id="DDI-PubMed.24925712.s6.e2" text="N" /><entity charOffset="243-244" id="DDI-PubMed.24925712.s6.e3" text="N" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e0" e2="DDI-PubMed.24925712.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e0" e2="DDI-PubMed.24925712.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e0" e2="DDI-PubMed.24925712.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e0" e2="DDI-PubMed.24925712.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e1" e2="DDI-PubMed.24925712.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e1" e2="DDI-PubMed.24925712.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e1" e2="DDI-PubMed.24925712.s6.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e2" e2="DDI-PubMed.24925712.s6.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s6.e2" e2="DDI-PubMed.24925712.s6.e3" /></sentence><sentence text=" Administration of sofosbuvir with OC did not alter PK of norelgestromin (primary norgestimate metabolite) or ethinyl estradiol"><entity charOffset="19-29" id="DDI-PubMed.24925712.s7.e0" text="sofosbuvir" /><entity charOffset="58-72" id="DDI-PubMed.24925712.s7.e1" text="norelgestromin" /><entity charOffset="110-127" id="DDI-PubMed.24925712.s7.e2" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.24925712.s7.e0" e2="DDI-PubMed.24925712.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s7.e0" e2="DDI-PubMed.24925712.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s7.e0" e2="DDI-PubMed.24925712.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s7.e1" e2="DDI-PubMed.24925712.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s7.e1" e2="DDI-PubMed.24925712.s7.e2" /></sentence><sentence text=" Small increases in norgestrel (secondary norgestimate metabolite) AUC(tau) (19%) and C(tau) (23%) with sofosbuvir were noted"><entity charOffset="104-114" id="DDI-PubMed.24925712.s8.e0" text="sofosbuvir" /></sentence><sentence text=" Ledipasvir did not impact PK of norelgestromin or norgestrel but modestly increased ethinyl estradiol C(max) (40%)"><entity charOffset="1-11" id="DDI-PubMed.24925712.s9.e0" text="Ledipasvir" /><entity charOffset="33-47" id="DDI-PubMed.24925712.s9.e1" text="norelgestromin" /><entity charOffset="51-61" id="DDI-PubMed.24925712.s9.e2" text="norgestrel" /><entity charOffset="85-102" id="DDI-PubMed.24925712.s9.e3" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e0" e2="DDI-PubMed.24925712.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e0" e2="DDI-PubMed.24925712.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e0" e2="DDI-PubMed.24925712.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e0" e2="DDI-PubMed.24925712.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e1" e2="DDI-PubMed.24925712.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e1" e2="DDI-PubMed.24925712.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e1" e2="DDI-PubMed.24925712.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e2" e2="DDI-PubMed.24925712.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s9.e2" e2="DDI-PubMed.24925712.s9.e3" /></sentence><sentence text=" Sofosbuvir, GS- 331007 (predominant circulating metabolite of SOF), and ledipasvir PK were similar to historical data"><entity charOffset="1-11" id="DDI-PubMed.24925712.s10.e0" text="Sofosbuvir" /></sentence><sentence text=" Pharmacodynamic markers luteinizing hormone, follicle-stimulating hormone, and progesterone values were generally comparable in all cycles"><entity charOffset="80-92" id="DDI-PubMed.24925712.s11.e0" text="progesterone" /></sentence><sentence text=" No loss in contraceptive efficacy is expected upon administration of sofosbuvir or ledipasvir/sofosbuvir with oral contraceptives containing norgestimate and ethinyl estradiol"><entity charOffset="70-80" id="DDI-PubMed.24925712.s12.e0" text="sofosbuvir" /><entity charOffset="84-94" id="DDI-PubMed.24925712.s12.e1" text="ledipasvir" /><entity charOffset="95-105" id="DDI-PubMed.24925712.s12.e2" text="sofosbuvir" /><entity charOffset="142-154" id="DDI-PubMed.24925712.s12.e3" text="norgestimate" /><entity charOffset="159-176" id="DDI-PubMed.24925712.s12.e4" text="ethinyl estradiol" /><entity charOffset="1-17" id="DDI-PubMed.24925712.s12.e5" text="N" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e5" e2="DDI-PubMed.24925712.s12.e5" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e5" e2="DDI-PubMed.24925712.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e5" e2="DDI-PubMed.24925712.s12.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e5" e2="DDI-PubMed.24925712.s12.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e5" e2="DDI-PubMed.24925712.s12.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e5" e2="DDI-PubMed.24925712.s12.e4" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e0" e2="DDI-PubMed.24925712.s12.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e0" e2="DDI-PubMed.24925712.s12.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e0" e2="DDI-PubMed.24925712.s12.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e0" e2="DDI-PubMed.24925712.s12.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e0" e2="DDI-PubMed.24925712.s12.e4" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e1" e2="DDI-PubMed.24925712.s12.e1" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e1" e2="DDI-PubMed.24925712.s12.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e1" e2="DDI-PubMed.24925712.s12.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e1" e2="DDI-PubMed.24925712.s12.e4" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e2" e2="DDI-PubMed.24925712.s12.e2" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e2" e2="DDI-PubMed.24925712.s12.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e2" e2="DDI-PubMed.24925712.s12.e4" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e3" e2="DDI-PubMed.24925712.s12.e3" /><pair ddi="false" e1="DDI-PubMed.24925712.s12.e3" e2="DDI-PubMed.24925712.s12.e4" /></sentence><sentence text=" The use of sofosbuvir or ledipasvir/sofosbuvir FDC with oral contraceptives is permitted"><entity charOffset="12-22" id="DDI-PubMed.24925712.s13.e0" text="sofosbuvir" /><entity charOffset="26-36" id="DDI-PubMed.24925712.s13.e1" text="ledipasvir" /><pair ddi="false" e1="DDI-PubMed.24925712.s13.e0" e2="DDI-PubMed.24925712.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24925712.s13.e0" e2="DDI-PubMed.24925712.s13.e1" /></sentence><sentence text="" /></document>